Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-22BP in Refractory Malignant Solid Tumors
NCT07040943Phase 1Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2025
- Primary completion
- Jan 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IL-22 binding protein in solid tumor, sponsored by West China Hospital of Sichuan University. Primary endpoint: Number of Participants with Dose-Limiting Toxicity and Treatment-Related Adverse Event at 2 months. Started Jun 2025; status: completed.
02
Drugs
IL-22 binding protein
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07040943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07040943.